Biopharma Safety Side effects 
European Pharmaceutical Review
NOVEMBER 18, 2022
The product, produced by biopharma company PTC Therapeutics, is approved for patients 18 months and over. The most common side effects observed were initial insomnia, irritability and dyskinesia. The efficacy and safety profile of Upstaza has been shown across clinical trials and compassionate use programmes.
pharmaphorum
JULY 1, 2022
billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. Those changes haven’t been enough to prevent the FDA from taking action, although outside the US the studies will continue as planned with the tighter safety monitoring.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 3, 2023
The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months. .
European Pharmaceutical Review
DECEMBER 7, 2022
Biopharma Akeso Inc. state the therapy could help reduce side effects and safety concerns. has announced it will enter into a collaboration potentially worth up to $5 billion with Summit Therapeutics Inc., Under the agreement, Akeso Inc. will receive a $500 million upfront payment. A $5 billion collaboration.
pharmaphorum
SEPTEMBER 28, 2022
In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.
pharmaphorum
DECEMBER 28, 2022
billion buyout of Principia Biopharma. That could give the drugs an advantage over CD20-targeting therapies like Roche’s Ocrevus (ocrelizumab) that inhibit B cells across the board, leaving patients prone to infections and other side effects.
PM360
JUNE 24, 2024
As we enter into the age of precision medicine, AI will be a critical tool to determine, with the help of disease knowledge graphs, which indications, associations, contraindications, side effects, genetic markers, drug targets, drug carriers, and interactions to take into account on a case-by-case basis. AI isn’t coming for your job.
Expert insights. Personalized for you.
126 
Let's personalize your content